nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.01.2014 | Original Paper

Cumulative probability of prostate cancer detection in biopsy according to free/total PSA ratio in men with total PSA levels of 2.1–10.0 ng/ml at population screening

verfasst von: Yasuhide Kitagawa, Satoru Ueno, Kouji Izumi, Yoshifumi Kadono, Hiroyuki Konaka, Atsushi Mizokami, Mikio Namiki

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The aim of this study was to investigate the cumulative probability of prostate cancer detection according to free/total prostate-specific antigen (PSA) ratio in men with PSA levels of 2.1–10.0 ng/ml and also likelihood of detecting clinically insignificant prostate cancer in population-based screening.

Methods

A total of 1,277 men aged between 55 and 69 years with total PSA (tPSA) levels of 2.1–10.0 ng/ml screened in population screening in Kanazawa city and underwent systematic transrectal ultrasonography-guided prostate biopsy between 2000 and 2011 were enrolled. The cumulative probability of prostate cancer detection in biopsy according to age, serum tPSA, and free-to-total PSA (f/t PSA) ratio was investigated. The clinicopathological features of screening-detected prostate cancer were also investigated.

Results

Of the 1,277 subjects in the study population, 320 (25.0 %) were diagnosed with prostate cancer during the observation period. The probabilities of prostate cancer detection at 3 years were 64.5, 41.2, 28.5, and 14.3 % for the men with f/t PSA ratio ≤0.08, 0.09–0.13, 0.14–0.22, and ≥0.23, respectively; the differences in probabilities of prostate cancer detection among men with different f/t PSA ratios were statistically significant. Among 320 patients, 84 (26.3 %) had favorable clinicopathological features that made them suitable for active surveillance. The f/t PSA ratio in unfavorable cancer patients was significantly lower that that in favorable cancer patients.

Conclusion

The present study demonstrated that the f/t PSA ratio was a strong predictor of future cancer detection and unfavorable cancerous features in prostate biopsy in men with total PSA levels of 2.1–10.0 ng/ml at population screening.

Andriole GL, Levin DL, Crawford ED et al (2005) Prostate cancer screening in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial: findings from the initial screening round of a randomized trial. J Natl Cancer Inst 97:433–438PubMedCrossRef

Argangeli CG, Humphrey PA, Smith DS et al (1998) Percentage of free serum prostate-specific antigen as a predictor of pathologic features of prostate cancer in a screening population. Urology 51:558–565CrossRef

Aus G, Becker C, Franzén S, Linja H, Lodding P, Hugosson J (2004) Cumulative prostate cancer risk assessment with the aid of the free-to-total prostate specific antigen ratio. Eur Urol 45:160–165PubMedCrossRef

Bouchardy C, Fioretta G, Rapiti E et al (2008) Recent trends in prostate cancer mortality show a continuous decrease in several countries. Int J Cancer 123:421–429PubMedCrossRef

Cancer International Union Against (1997) Urologic tumors: prostate. In: Sobin LH, Wittekind CH (eds) TNM classification of malignant tumours, 5th edn. John Wiley and Sons, New York, pp 170–173

Carter HB, Albertsen PC, Barry MJ et al (2013) Early detection of prostate cancer: AUA guideline. J Urol 190:419–426PubMedCrossRef

Catalona WJ, Smith DS, Ratliff TL et al (1991) Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. New Engl J Med 324:1156–1161PubMedCrossRef

Crawford ED, Moul JW, Rove KO et al (2011) Prostate-specific antigen 1.5–4.0 ng/ml: a diagnostic challenge and danger zone. BJU Int 108:1743–1749PubMedCrossRef

Finne P, Auvinen A, Määttänen L et al (2008) Diagnostic value of free prostate-specific antigen among men with a prostate-specific antigen level of <3.0 μg/l. Eur Urol 54:362–370PubMedCrossRef

Ishidoya S, Ito A, Orikasa K et al (2008) The outcome of prostate cancer screening in a normal Japanese population with PSA of 2–4 ng/ml and the free/total PSA under 12%. Jap J Clin Oncol 38:844–848CrossRef

Ito K, Yamamoto T, Ohi M et al (2003) Free/total PSA ratio is a powerful predictor of future prostate cancer morbidity in men with initial PSA levels of 4.1–10.0 ng/ml. Urology 61:760–764PubMedCrossRef

Kakehi Y, Kamoto T, Shiraishi T et al (2008) Prospective evaluation of selection criteria for active surveillance in Japanese patients with stage T1cN0M0 prostate cancer. Jpn J Clin Oncol 38:122–128PubMedCrossRef

Kitagawa Y, Mizokami A, Nakashima K et al (2011) Clinical outcomes of prostate cancer patients detected by prostate-specific antigen-based population screening in Kanazawa city. Jpn Int J Urol 18:592–596CrossRef

Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A (2010) Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 28:126–131PubMedCrossRef

Kobori Y, Kitagawa Y, Mizokami A, Komatsu K, Namiki M (2008) Free-to-total prostate-specific antigen (PSA) ratio contributes to an increased rate of prostate cancer detection in a Japanese population screened using a PSA level of 2.1–10.0 ng/ml as a criterion. Int J Clin Oncol 13:229–232PubMedCrossRef

Orsted DD, Nordestgaard BG, Jensen GB, Schnohr P, Bojesen SE (2012) Prostate-specific antigen and long-term prediction of prostate cancer incidence and mortality in the general population. Eur Urol 61:865–874PubMedCrossRef

Pannek J, Rittenhouse HG, Chan DW et al (1998) The use of percent free prostate specific antigen for staging clinically localized prostate cancer. J Urol 159:1238–1242PubMedCrossRef

Pelzer AE, Volgger H, Bektic J et al (2005) The effect of percentage free prostate-specific antigen (PSA) level on the prostate cancer detection rate in a screening population with low PSA levels. BJU Int 96:995–998PubMedCrossRef

Roddam AW, Duffy MJ, Hamdy FC et al (2005) Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2–10 ng/ml: systematic review and meta-analysis. Eur Urol 48:386–399PubMedCrossRef

Schröder FH (2001) Diagnosis, characterization and potential clinical relevance of prostate cancer detected at low PSA ranges. Eur Urol 39:49–53PubMedCrossRef

Thompson IM, Pauler DK, Goodman PJ et al (2004) Prevalence of prostate cancer among men with a prostate-specific antigen levels ≤4.0 ng/ml. N Engl J Med 350:2239–2246PubMedCrossRef

Titel: Cumulative probability of prostate cancer detection in biopsy according to free/total PSA ratio in men with total PSA levels of 2.1–10.0 ng/ml at population screening
verfasst von: Yasuhide Kitagawa
Satoru Ueno
Kouji Izumi
Yoshifumi Kadono
Hiroyuki Konaka
Atsushi Mizokami
Mikio Namiki
Publikationsdatum: 01.01.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 1/2014
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-013-1543-9

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Cumulative probability of prostate cancer detection in biopsy according to free/total PSA ratio in men with total PSA levels of 2.1–10.0 ng/ml at population screening

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2014

Sodium taurocholate cotransporting polypeptide mediates dual actions of deoxycholic acid in human hepatocellular carcinoma cells: enhanced apoptosis versus growth stimulation

FDG PET/CT metabolic tumor volume and total lesion glycolysis predict prognosis in patients with advanced lung adenocarcinoma

Low CADM2 expression predicts high recurrence risk of hepatocellular carcinoma patients after hepatectomy

Breast cancer adaptive resistance: HER2 and cancer stem cell repopulation in a heterogeneous tumor society

Effect of neoadjuvant treatment in the management of osteosarcomas of the head and neck

Digital PCR quantification of miRNAs in sputum for diagnosis of lung cancer

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie